SAGES Magazine

THE SOUTH AFRICAN GASTROENTEROLOGY REVIEW 2022 | VOLUME 20 | ISSUE 3 | 11 Thesis in medicine. Dakar, 2010, n°63, 139p. 3. Lunel-Fabiani F, Mansour W, Amar AO, Aye M, Le Gal F, Malick F-ZF, Baïdy L, Brichler S, Veillon P, Ducancelle A, Gordien E, Rosenheim M. Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: A cross sectional study. J Infect 2013, 67:448-457 4. Papa Saliou M’BAYE. Epidemiology of viral hepatitis in sub- Saharan Africa. 18th AAFFCHGE Congress - 28th SAGHEED Congress - Algiers, 15-17 December 2016 5. Foupouapouognigni Y, Noah DN, Sartre MT, Njouom R. High Prevalence and Predominance of Hepatitis Delta Virus Genotype 1 Infection in Cameroon. J Clin Microbiol 2011, 49:1162-1164 6. Sawadogo A, Ouédraogo AS, Poda A, Dahourou H, Pivert A, Mansour W, Ducancelle A, Lunel-Fabiani F. Seroprevalence of hepatitis D virus infection in a population of blood donors carrying HBs Antigen at the Bobo-Dioulasso Regional Blood Transfusion Centre. J Afr Hepato-Gastroenterology 2016,10:31- 33 7. Meda N, Tuaillon E, Kania D, Tiendrebeogo A, Pisoni A, Zida S, et al. Hepatitis B and C virus seroprevalence, Burkina Faso: a cross-sectional study. Bull World Health Organ. 2018 Nov 1;96(11):750-9. doi: http:// dx .doi .org/ 10.2471/ BLT .18 .208603 PMID: 30455530 8. Asmah RH, Boamah I, Afodzinu M, Brown CA, Brandful J, Adjei DN, Adiku T, Gyasi R, Wireder EK. Prevalence of hepatitis d infection in patients with hepatitis B virus-related liver diseases in Accra, Ghana. West Afr Journal Med 2014, 33:32-6 9. Sawadogo A, Ouédraogo AS, Poda A, Dahourou H, Pivert A, Mansour W, Ducancelle A, Lunel-Fabiani F. Seroprevalence of hepatitis D virus infection in a population of blood donors carrying the HBs Antigen at the Bobo-Dioulasso Regional Blood Transfusion Centre. J Afr Hepato-Gastroenterology 2016,10:31- 33 10. Vray M, Debonne J-M, Sire J-M, Tran N, Chevalier B, Plantier J-C, Fall F, Vernet G, Simon F, M’baye PS. Molecular epidemiology of hepatitis B virus in Dakar, Senegal. J Med Virol 2006, 78:329-334 11. Ghorachi Mint Mohamed Mahmoud. Impact of delta virus infection on the natural history of hepatitis B in Mauritania. Thesis in medicine. Dakar, 2010, n°63, 139p. 12. Mansour Wael. Prevalence and genetic diversity of circulating HBV and HDV strains in Niger and Mauritania. Microbiology and Parasitology. University of Angers, 2012. 13. De Paschale M, Ceriani C, Cerulli T, Cagnin D, Cavallari S, Ndayaké J, Zaongo D, Priuli G, Viganò P, Clerici P. Prevalence of HBV, HDV, HCV, and HIV infection during pregnancy in northern Benin. J Med Virol 2014, 86:1281-1287 14. Asmah RH, Boamah I, Afodzinu M, Brown CA, Brandful J, Adjei DN, Adiku T, Gyasi R, Wireder EK. Prevalence of hepatitis d infection in patients with hepatitis B virus-related liver diseases in Accra, Ghana. West Afr Journal Med 2014, 33:32-6 15. Ducancelle A, Abgueguen P, Birguel J, Mansour W, Pivert A, Le Guillou-Guillemette H, Sobnangou J-J, Rameau A, Huraux J-M, Lunel-Fabiani F. High endemicity and low molecular diversity of hepatitis B virus infections in pregnant women in a rural district of North Cameroon. PLoS ONE 2013, 8:11 16. Djebbi A, Rebai WK, Bahri O, Hogga N, Sadraoui A, Triki H. Serological markers, viral RNA and genotype of hepatitis delta virus in HBsAg positive Tunisian patients. Pathol Biol 2009, 57:518-523 17. D Roulot. Hepatitis delta in 2016:virus, markers, epidemiology, natural history, treatment. University of Paris 13. Presentation 2016 18. Kao J-H, Chen P-J, Lai M-Y, Chen D-S. Hepatitis D Virus Genotypes in Intravenous Drug Users in Taiwan: Decreasing Prevalence and Lack of Correlation with Hepatitis B Virus Genotypes. J Clin Microbiol 2002, 40:3047-3049 19. Blumberg BS, Alter HJ, Visnichs A. Australia antigen and the revolution in hepatology. Calif Med 1972 Apr, 116 (4):28-34 20. Moatter T. Clinical presentation and genotype of hepatitis delta in Karachi. World J Gastroenterol 2007, 13:2604 21. Onyekwere CA, Audu RA, Duro-Emmanuel F, Ige FA. Hepatitis D infection in Nigeria. Indian J Gastroenterol 2012, 31 :34-35 22. Ghorachi Mint Mohamed Mahmoud. Impact of delta virus infection on the natural history of hepatitis B in Mauritania. Thesis in medicine. Dakar, 2010, n°63, 139p. 23. Mansour W, Bollahi M-A, Hamed C-T, Brichler S, Le Gal F, Ducancelle A, Lô B, Gordien E, Rosenheim M, Lunel F. Virological and epidemiological features of hepatitis delta infection among blood donors in Nouakchott, Mauritania. J Clin Virol 2012, 55:12-16 24. Huang C, Chang SC, Yu I-C, Tsay Y-G, Chang M-F. Large Hepatitis Delta Antigen Is a Novel Clathrin Adaptor-Like Protein. J Virol 2007, 81:5985-5994 25. M Rizzetto, Hoyer B, Canese MG, Shih JW, Purcell RH, Gerin JL. Delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Nati Acad Sci USA 1980, 77: 6224-6128 26. Taylor JM. Structure and Replication of Hepatitis Delta Virus RNA. Curr Top Microbiol Immunol 2006, 307:1-23 27. Simon A. Walley, John M.Murray, Dave Brown, Gearge J.M. Webster, Vincent C.Emery, Geoffrey M.Dusheiko, Alan S.Perelson. Kinetics of Acute Hepatitis B Virus Infection in Humans. J Med Virol 2001, 193:847-854 28. F Bossali, Koumou Okandze L, Katende S, Thouassa A. Seroprevalence of hepatitis B in patients with cirrhosis and in patients with hepatocellular carcinoma in Pointe-Noire from 2005 to 2008. J Afr Hépato-Gastroentérologie 2011, 5:2-5 29. Rossi C, Shrier I, Marshall L, Cnossen S, Schwartzman K, Klein MB, Schwarzer G, Greenaway C. Seroprevalence of Chronic Hepatitis B Virus Infection and Prior 30. Immunity in Immigrants and Refugees: A Systematic Review and Meta-Analysis. PLoS ONE 2012, 7:11 31. Sawadogo Windyam Abdoulaye. Study of the epidemiological, clinical, paraclinical, etiological and evolutionary aspects of liver cirrhosis in the Department of Medicine of the CHUSS of Bobo- Dioulasso: About 87 cases. Thesis medicine. Ouagadougou, 2012, n°117, 150p. 32. Zouré Nogogna. Treatment of chronic hepatitis B with nucleotide analogues in cirrhotic patients at the Centre Hospitalier Universitaire Yalgado Ouedraogo de Ouagadougou: about 38 cases. Annale de l’université joseph ki-zerbo. série d, vol. 027, december 2021 - tome 1 - issn2424-7553 33. Sawadogo A, Dib N, Cales P. Pathophysiology of cirrhosis and its complications. Réanimation 2007, 16:557-562 34. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F, Tacke F. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017, 67:370-398 35. Sombié R, Sangaré L, Guingané A, Tiendrébéogo A, Kaboré D, Bougouma A. Treatment of chronic hepatitis B with nucleos(t) ides analogues. J Afr Hepato- Gastroenterology 2015, 9:114- 118 36. Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C et al. Long-term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of Hepatitis B Virus- Related Cirrhosis. Clin Gastroenterol Hepatol 2013, 11:88-94 37. Liaw Y-F, Sheen I-S, Lee C-M, Akarca US, Papatheodoridis GV, Suet-Hing Wong F et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011, 53:62-72 38. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot- Peignoux M, Byer N, Pham BN, Maylin S, Bedossa P, Gault E, Dény P, Marcellin P. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up. Hepatology 2006, 44:728-735 REVIEW GPA’s Non-PPI (Antacids, H2 blockers) PPI Habits Smoker Alcohol use Indication Headache Musculoskelet Gastrointestin Other Pattern of use General advic Take with mea Frequency Daily Twice daily Three times d Four times dai >Four times daily NSAID non-steroidal the counter; GPA’s ga pump inhibitors; H2 h Discussion The South African Ess ibuprofen as an altern first line management for ibuprofen, and co common in South Afri tertiary hospitals in th where patterns of OT UGIT bleeds have not During the study p wh were admitted w 85% (n=183) of who prescription. This is fa groups in first world c admitted for UGIT ha The implication is that particular low socioec obtained and users ar information to guide t In this study the thr UGIT bleeds requirin age, multiple medical Age Advanced age itself h risk factor for UGIT bl reported risk factor fo Approximately 40-60 years of age 8 , and up NSAID’s may obtain t individuals in this stu (n=72) used NSAIDS them OTC. In the We patients suffering fro recent years, mostly widespread NSAID u than 60 years of age h to 4.1 million (2011) w Current socio-econo the elderly population medication and 28 % of the fact that the risk 1.65 per 100 000 in p those >65 years and